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In 2019, only 14 European and Central Asian countries 
provided reimbursed HIV pre-exposure prophylaxis 
(PrEP). Using EMIS-2017 data, we present the differ-
ence between self-reported use and expressed need 
for PrEP in individual countries and the European 
Union (EU). We estimate that 500,000 men who have 
sex with men in the EU cannot access PrEP, although 
they would be very likely to use it. PrEP’s potential 
to eliminate HIV is currently unrealised by national 
healthcare systems.
The international community has committed to the 
Sustainable Development Goal of ending the AIDS epi-
demic by 2030 (SDG 3.3). Pre-exposure prophylaxis 
(PrEP) for HIV infection involves the use of antiretrovi-
ral drugs by people at high risk of acquiring HIV. The 
efficacy of PrEP is well-documented [1-3]. Research in 
New South Wales, Australia, indicates that population-
level impact of PrEP on HIV can be achieved among 
men who have sex with men (MSM) with a targeted, 
accessible programme [4]. To achieve SDG 3.3, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) has 
recommended as one of its global targets that 3 million 
people access PrEP by 2020 [5].
Following publication of the PROUD [2] and Ipergay 
[3] studies in 2015, the European Centre for Disease 
Prevention and Control (ECDC) released an opinion 
that European Union (EU) countries should consider 
integrating PrEP into their existing HIV prevention pro-
grammes for those most at risk of HIV infection [6]. The 
World Health Organization (WHO) has made the same 
recommendation for countries globally [7]. Here we 
describe the progress made by countries in Europe and 
Central Asia (the 53 countries of the WHO European 
Region plus Kosovo* and Liechtenstein) in implement-
ing PrEP and estimate the gap between PrEP access 
and expressed need [8] at country and at EU level.
Monitoring PrEP implementation in 
Europe and Central Asia
The ECDC disseminates an annual online survey to 
nominated HIV focal points, usually national health 
authority representatives, in the 31 countries of 
the EU and European Economic Area (EEA) to moni-
tor the implementation of the Dublin Declaration on 
Partnership to Fight HIV/AIDS and progress towards 
achieving SDG 3.3 [9]. Data for the remaining 24 coun-
tries in Europe and Central Asia are supplemented with 
Global AIDS Monitoring (GAM) indicators collected by 
UNAIDS. Since 2016, the survey has included ques-
tions on PrEP availability, implementation and barriers 
to implementation.
The most recent survey was conducted between 
January and March 2019. Countries were asked to 
respond in relation to the most recent reporting year. 
Of the 55 countries surveyed by ECDC and UNAIDS, 53 
provided data – the exceptions being San Marino and 
Turkmenistan. Data reported online were validated by 
the countries and updated accordingly.
We also examined data on self-reported PrEP use 
and expressed need for PrEP from the European MSM 
Internet Survey (EMIS-2017), conducted in 33 lan-
guages with 127,000 MSM from 47 of the 55 countries 
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in Europe and Central Asia between October 2017 and 
January 2018 [10,11]. The eight countries not covered 
by EMIS-2017 were: Armenia, Azerbaijan, Georgia, 
Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and 
Uzbekistan. When using EMIS figures, data from the 
four European microstates Andorra, Liechtenstein, 
Monaco and San Marino were merged with those from, 
respectively, Spain, Switzerland, France and Italy.
Implementation of PrEP in Europe and 
Central Asia
Data collected via Dublin Declaration monitoring pro-
vide a snapshot of a rapidly changing situation on state 
PrEP provision with substantial diversity across the 
Region (Figure 1). By 2019, 14 of 53 reporting countries 
reported that their national health service provided 
reimbursed PrEP (Belgium, Bosnia and Herzegovina, 
Croatia, Denmark, France, Germany, Iceland, 
Luxembourg, Moldova, the Netherlands, Norway, 
Portugal, Sweden, and Northern Ireland and Scotland 
within the United Kingdom (UK)), either through insur-
ance or from the public sector. The results show that 
progress has been made since 2016, when only France 
reported that PrEP was nationally available and reim-
bursed [12].
Ten countries reported that generic PrEP was available 
in healthcare settings, but it was not fully reimbursed 
(Armenia, Austria, the Czech Republic, Finland, Ireland, 
Israel, Italy, Malta, Poland and Switzerland).
Six countries report PrEP availability only through 
pilot, research or demonstration projects at national or 
sub-national level (Georgia, Greece, Slovenia, Spain, 
Ukraine, and England and Wales within the UK). It is 
important to note that the degree of access to PrEP 
in such projects varied considerably. For example, 
England and Wales saw 6,000 people access PrEP in 
the 12 months before reporting in 2019, while Ukraine 
saw 125 people access PrEP in the same period.
Barriers to implementing PrEP in Europe 
and Central Asia
Of the 40 countries reporting that PrEP was not 
nationally available and reimbursed (including the UK 
because of regional differences), 32 countries provided 
data on barriers to implementation (Figure 2). The most 
Figure 1
Status of PrEP implementation, Dublin Declaration monitoring in Europe and Central Asia, September 2019 (n = 53)
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PrEP: pre-exposure HIV prophylaxis.
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commonly cited barrier to implementing PrEP was the 
cost of the drug. Of the 24 countries reporting high drug 
costs, 15 stated that cost was a high-importance bar-
rier with a further seven citing a medium-importance 
barrier. Although outweighed by concerns relating to 
cost and service delivery, concerns about the impact of 
PrEP on sexual behaviours and epidemiology persisted 
in 18 countries.
Use of PrEP in Europe and Central Asia
Twenty countries reported national estimates of the 
number of people using PrEP in the last 12 months 
(Figure 3). Only Switzerland and Germany reported that 
they were able to capture or adjust for self-sourced 
PrEP use within these estimates. The number and rate 
of people using PrEP at least once varied substantially; 
the number ranged from one PrEP user (Moldova) to 
9,078 PrEP users (France) and the rate ranged from 
0.04 to 52.5 per 100,000 adult population (aged 15–64 
years). In most countries for which data were provided, 
the majority of PrEP users had used PrEP for the first 
time in the last 12 months.
Fifteen of the 20 countries provided data disaggre-
gated by sex and probable transmission route, with 12 
reporting that more than 90% of PrEP users were MSM. 
Belgium, Denmark, Ireland, Israel, Portugal, Spain and 
Sweden reported PrEP provision in their country but 
were unable to provide the number of people using 
PrEP.
Estimating the PrEP gap among men who 
have sex with men
The EMIS-2017 collected data on both the proportion of 
respondents currently using PrEP and those who would 
be ‘very likely’ to use PrEP if they could access it. The 
difference between these two proportions provides an 
estimate of the ‘PrEP gap’ or the level of unmet need 
for PrEP in each country.
To calculate the PrEP gap we used EMIS-2017 data on 
PrEP use rather than country-reported numbers as data 
on use was available for a wider range of countries from 
EMIS-2017 and because EMIS-2017 captured PrEP use 
from any source whereas most country-reported data 
were not able to capture or adjust for self-sourced PrEP.
We chose to use the proportion of EMIS-2017 respond-
ents who would be ‘very likely’ to use PrEP if it was 
available to them as the indicator of need. Studies 
show a positive correlation between the willingness of 
MSM to use PrEP and an increased risk of acquiring HIV 
Figure 2
Country reported barriers to implementing PrEP, Dublin Declaration monitoring in Europe and Central Asia, 2018 (n = 32 
countries)
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transmitted infections
Feasibility
Cost of service delivery
The technical capacity to consider PrEP is limited
Cost of the drug
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Number of reporting countries
PrEP: pre-exposure HIV prophylaxis; WHO: World Health Organization.
Data in this figure are from 2018, as the question on barriers to PrEP implementation was not asked in 2019.
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sexually [13]. Our measure is therefore of expressed 
need for PrEP rather than ‘normative need’ (the crite-
ria for PrEP access defined by experts and expressed 
in guidelines) [8]. As guidelines differ by country, the 
same group of MSM would be judged to have different 
levels of normative need depending on which country 
they lived in.
The estimated PrEP gap ranged from 44.8% in Russia 
to 4.3% in Portugal (Figure 4). An overall estimate of 
the PrEP gap for the EU was calculated as 17.4%. Based 
on the assumption that 2.77% (95% confidence inter-
val (CI): 2.31–3.32%) [14] of the adult male population 
in the EU are MSM and applying an adjustment factor 
of 1.6 to counter for self-selection bias [15], an esti-
mated 500,000 (95% CI: 420,000–610,000) MSM are 
not currently using PrEP but would be very likely to do 
so if they could access it.
We assume that the fundamental reason for this gap 
is that in the majority of countries, easy access to 
free or subsidised PrEP is either not possible or not 
easy.  Figure 4  illustrates that in the countries where 
formal PrEP provision occurs, the gap was smaller and 
in countries where there is no formal access, it was 
larger.
Limitations
Country-reported data underestimate the actual num-
ber of PrEP users in some countries since many coun-
tries are not able to capture or adjust for self-sourced 
PrEP and because many health authorities struggle 
to systematically capture data on state-provided PrEP 
because of the diverse institutions providing it, a lack 
of data exchange between institutions and anonymisa-
tion of data (preventing identification of duplication).
Figure 3
People using PrEP in the last 12 months, by rate per 100,000 adult populationa, Dublin Declaration monitoring in Europe 
and Central Asia, 2019 (n = 20)
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PrEP: pre-exposure HIV prophylaxis.
a Adult population here defined as age 15 to 64 years.
The data labels in brackets represent the numbers of people using PrEP at least once in the last 12 months. The Netherlands, Norway, 
Switzerland and the United Kingdom were unable to provide estimates for the number of people using PrEP for the first time in the last 12 
months. Italy was unable to provide an estimate for the number of people using PrEP at least once in the last 12 months so the data label 
for Italy represents the number of people using PrEP for the first time in the last 12 months.
These data are correct as of March 2019.
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Figure 4
The PrEP Gap – the proportion of non-HIV-diagnosed MSM ‘very likely’ to use PrEP if accessible, compared with 
the proportion currently using PrEP from any source, EMIS-2017 qualifying countries, January 2018 (n=44 countries; 
n = 112,748 respondents)
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When calculating the rate of people using PrEP per 
100,000 of the adult population (with adult defined as 
15–64 years) we were unable to exclude those aged 65 
or over as data were not disaggregated by age.
The figure of 500,000 MSM in the EU likely to use 
PrEP if it were accessible may be an overestimate 
since EMIS-2017 used an MSM convenience sample 
which is known to over-represent the more sexually 
active. However, given that the calculation included 
only respondents who said they would be ‘very likely’ 
to use PrEP (as opposed to also including those who 
were ‘quite likely’) and because we used a factor to 
adjust for oversampling MSM at higher risk, we believe 
this is the best available estimate. As intention to use 
PrEP seemed particularly high in countries with larger 
populations such as Russia and Turkey and because 
EMIS-2017 lacks data from Central Asian countries, we 
restricted the calculation of the absolute numbers to 
the EU region.
We were able to estimate the PrEP gap only for MSM 
as we do not have an equivalent data source to EMIS-
2017 for other key populations in need of PrEP. Where 
countries were able to provide disaggregated data on 
PrEP users, the majority indicated that less than 10% of 
PrEP users were either women (including trans women) 
or heterosexual men. Only two countries were able to 
provide data on PrEP users who inject drugs or engage 
in sex work.
Conclusion
This paper represents the first attempt to quantify the 
PrEP gap for MSM in 47 EMIS-2017 qualifying countries 
[11] and at the EU level. At a time when provision of 
PrEP is rapidly increasing, these findings contribute to 
our understanding of PrEP implementation and use in 
Europe and Central Asia. Although significant progress 
has been made since 2016, with 14 countries now 
providing and reimbursing PrEP within their national 
health system, PrEP implementation remains vari-
able across the Region. In order to accelerate progress 
towards SDG 3.3, ending the AIDS epidemic by 2030, 
much wider implementation of PrEP will be required.
Sex between men remains the predominant mode 
of HIV transmission reported in Western and Central 
Europe, accounting for half of all new HIV diagnoses 
where the transmission route is known [16]. Despite 
this, ca 500,000 MSM in the EU who are very likely to 
use PrEP are not currently able to access it. The longer 
the delay in access to PrEP for these men, the more HIV 
infections will occur.
In order to facilitate PrEP implementation across Europe 
and Central Asia, minimum standards on the principles 
of establishing PrEP programmes, monitoring and sur-
veillance would be beneficial. These should include 
guidance on identifying and estimating the size of key 
populations in need of PrEP which can then inform 
programme targets. National health authorities should 
focus on improving accessibility of PrEP to women and 
heterosexual men at high risk of HIV, as well as an 
expansion of PrEP availability more generally.
Note
*This designation is without prejudice to positions on status, 
and is in line with United Nations Security Council Resolution 
1244/99 and the International Court of Justice Opinion on the 
Kosovo Declaration of Independence.
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